BioSpace News Archive

The increasing importance of sustainable crop production is a prime factor augmenting the growth of the global plant phenotyping market.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that its recently acquired German subsidiary, AdVita Lifescience GmbH, has received regulatory clearance to commence a phase 2 clinical trial in Germany to evaluate inhaled aviptadil for the treatment of sarcoidosis.

Cortene Inc. announces publication of its InTiME clinical trial in which a short subcutaneous infusion of its experimental drug, CT38, achieved sustained symptom improvement in ME/CFS

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), today announced that Harmony’s President and CEO, John C. Jacobs, will participate in fireside chats and host investor meetings at the following upcoming virtual conferences

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Agiliti Inc. (NYSE: AGTI) (“Agiliti”), a nationwide provider of healthcare technology management and service solutions to the United States healthcare industry, today announced that the company will participate at the Morgan Stanley 19th Annual Global Healthcare Conference.

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has entered into an agreement with BIAL in which Sunovion has granted exclusive commercial license rights in Europe for apomorphine sublingual film (APL-130277)

Aldeyra Therapeutics, Inc., a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences.

Fluidigm Corporation announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the following investor event.

ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences.